Genedata Extends Lead Discovery Collaboration with Novartis
News May 16, 2006
Genedata’s agreement with Novartis includes round the clock support for the Genedata Screener® platform in Cambridge (MA), USA and Basel, Switzerland.
"Novartis sought an innovative partner to deliver advanced analysis and visualization tools for HTS analysis," explained Dr. Stephan Heyse, Head of Screener.
The collaboration with Genedata was initiated with Novartis Discovery Technologies, a core component of the NIBR.
Novartis cultivates close development partnerships through its Discovery Technologies program.
Successful collaborations are scaled-up and applied at the Company’s research sites globally.
Scientists at Novartis use Screener to pinpoint quality issues in screening data as part of a highly automated analysis workflow. The software is designed to validate entire screens in a standardized fashion.
Dr. Heyse added, "This saves time and minimizes the risk that lead compounds fail at later phases of drug development."
Bicycle Therapeutics Expands Strategic Partnership with AstraZenecaNews
New programs added in respiratory and cardio-metabolic diseases.READ MORE
Worldwide Clinical Trials Receives 2018 CRO Leadership AwardsNews
Life Science Leader and Industry Standard Research assess 70 contract research organizations, honoring Worldwide Clinical Trials for fifth consecutive year.READ MORE
WuXi Biologics to Invest in Biologics Manufacturing Facility in SingaporeNews
WuXi Biologics' first overseas site in Asia.READ MORE
Comments | 0 ADD COMMENT
2nd Annual Artificial Intelligence in Drug Development Congress
Sep 20 - Sep 21, 2018